Celltrion Healthcare has partnered with the University of Oxford and University Hospitals Birmingham to investigate the use of infliximab biosimilar CT-P13 as a treatment for COVID-19 symptoms.
For patients with early rheumatoid arthritis (RA) and high disease activity, the combination of a tumor necrosis factor (TNF) or non-TNF biologic with methotrexate improves disease control...